Floxuridine and Dexamethasone as a Hepatic Arterial Infusion and Bevacizumab in Treating Patients With Primary Liver Cancer That Cannot be Removed by Surgery

NCT00410956 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

22

Enrollment

OTHER

Sponsor class

Conditions

Liver Cancer

Interventions

BIOLOGICAL: bevacizumab
DRUG: dexamethasone
DRUG: floxuridine
GENETIC: protein expression analysis
OTHER: flow cytometry
OTHER: immunoenzyme technique
OTHER: immunohistochemistry staining method
OTHER: immunologic technique
OTHER: laboratory biomarker analysis
PROCEDURE: dynamic contrast-enhanced magnetic resonance imaging

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]